What question did this study set out to answer?

To evaluate minimal residual disease (MRD) kinetics and assess its predictive value for progression-free survival in patients with chronic lymphocytic leukemia receiving fixed-duration ibrutinib plus venetoclax.

June 6, 2023Journal of Clinical OncologyOpen Access

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

View Full Paper

Ask AI

Bookmark

Authors

TMTalha MunirIslamia University of Bahawalpur CMCarol MorenoUniversitat Autònoma de Barcelona COCarolyn OwenUniversity of Calgary

Discussion

Member takes

Implication

Randomized trial demonstrates sustained progression-free survival independent of minimal residual disease with ibrutinib-venetoclax in chronic lymphocytic leukemia, indicating durable disease control.

Key Points

To evaluate minimal residual disease (MRD) kinetics and assess its predictive value for progression-free survival in patients with chronic lymphocytic leukemia receiving fixed-duration ibrutinib plus venetoclax.
Assessed MRD kinetics and status in bone marrow and peripheral blood at 3 months post-treatment in previously untreated older/comorbid patients with chronic lymphocytic leukemia from the GLOW trial.
Compared outcomes between fixed-duration ibrutinib plus venetoclax and chlorambucil plus obinutuzumab, analyzing progression-free survival up to 12 months after treatment completion.
Bone marrow response rates were 83.3% and 58.7% in the chlorambucil plus obinutuzumab comparator arm.
Progression-free survival rates at 12 months post-treatment remained high in ibrutinib plus venetoclax recipients, including patients with unmutated IGHV, independent of bone marrow MRD status.

Cite This Study

Munir et al. (2023) studied this question.

synapsesocial.com/papers/6a03c3cd94ec7ec37ca9cfcc https://doi.org/10.1200/jco.22.02283

View Full Paper

Ask AI

Bookmark

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider